iPS Cells & Regenerative Medicine– category –
-
Groundbreaking CAR-T Cell Therapy Achievement: Multiple Myeloma Patient Attains Decade-Long Remission After Exhausting Chemotherapy Options
Stanford Medicine Facebook USA Overview A patient with advanced multiple myeloma achieved a remarkable 10-year remission after participating in a CAR-T cell therapy trial at the Fred and Pamela Buffett Cancer Center. Despite exhausting c... -
Building Commercial Readiness in Advanced Therapies: Optimizing Supply Chain, Manufacturing, and Regulatory Strategy is Critical
The Medicine Maker Unknown Overview Achieving commercial readiness for Advanced Therapy Medicinal Products (ATMPs), particularly cell and gene therapy products, is an urgent industry imperative. This requires establishing robust supply c... -
Clinical Progress of Engineered Cellular Immunotherapies for Autoimmunity: Diverse Modalities Pioneer New Treatment Avenues
PMC - NIH USA Overview Clinical development of engineered cellular immunotherapies for autoimmune diseases is rapidly advancing, poised to offer novel therapeutic options. Diverse modalities, including CAR-T cells, CAR-NK cells, and TCR-... -
Sumitomo Pharma Initiates First Patient Dosing in Phase 1/2a Trial of DSP-3077 for Schizophrenia
Clinical Trials Arena Unknown Overview Sumitomo Pharma (America) has commenced dosing the first patient in its Phase 1/2a clinical trial for DSP-3077, a novel therapeutic candidate for schizophrenia. DSP-3077 targets specific receptors r... -
Xilio Therapeutics Reports Q2 2026 Financial Results, Advances Tumor Microenvironment-Activated Immunotherapy Pipeline with Promising Early Clinical Data
GlobeNewswire USA Overview Xilio Therapeutics released its Q2 2026 financial results, reporting significant pipeline progress for its tumor microenvironment (TME)-activated immunotherapy candidates. Lead programs XTX101, XTX202, and XTX3... -
Epigenome Editing of Human Hematopoietic Stem Cells Achieves Sustained and Reversible Thrombosis Prevention
preLights (The Company of Biologists) Unknown Overview A groundbreaking study demonstrated that epigenome editing of human hematopoietic stem cells (HSCs) enables sustained and reversible thrombosis prevention. This innovative technology... -
Voyager Therapeutics Advances Two Tau-Targeted Alzheimer’s Therapies Towards Key Clinical Milestones
NeurologyLive USA Overview Voyager Therapeutics announced its progression of two innovative therapeutic candidates targeting tau protein, a key pathological hallmark of Alzheimer's disease, toward significant clinical milestones. These c... -
IPS HEART Secures FDA Rare Pediatric Disease Designation for Muscular Dystrophy-Associated Cardiomyopathies, Accelerating Cardiac Regenerative Medicine Development
BioSpace USA Overview IPS HEART has received Rare Pediatric Disease Designation (RPDD) from the U.S. FDA for its iPSC-derived therapeutic candidate for muscular dystrophy-associated cardiomyopathies. This marks the company's 8th FDA regu... -
In Vivo CAR-T Cell Therapy Achieves Clinical Proof of Concept; AI Integration Poised to Revolutionize Cancer Treatment
OncoDaily Unknown Overview In vivo CAR-T cell therapy has achieved initial clinical proof of concept, demonstrating its potential to transform cancer treatment. This novel approach directly delivers and expresses CAR genes in T-cells wit... -
CEA-Targeted CAR-NK Cells Derived from iPSCs Demonstrate Potent Anti-Tumor Activity Against Colorectal Cancer
Frontiers in Immunology Unknown Overview A new study reports that chimeric antigen receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) exhibit potent anti-tumor activity against colorectal cancer. These CEA-target...
